Ubs Group Ag Arcturus Therapeutics Holdings Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Ubs Group Ag holds 52,858 shares of ARCT stock, worth $873,742. This represents 0.0% of its overall portfolio holdings.

Number of Shares

52,858

Previous 62,159 14.96%

Holding current value

$873,742

Previous $1.51 Million 18.97%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$18.08 - $25.38 $168,162 - $236,059	-9,301 Reduced 14.96%	52,858 $1.23 Million
Q2 2024 Aug 13, 2024	SELL	$24.35 - $44.39 $1.11 Million - $2.03 Million	-45,780 Reduced 42.41%	62,159 $1.51 Million
Q1 2024 May 13, 2024	BUY	$31.23 - $42.99 $1.1 Million - $1.51 Million	35,231 Added 48.46%	107,939 $3.65 Million
Q4 2023 Feb 09, 2024	BUY	$17.71 - $32.97 $734,008 - $1.37 Million	41,446 Added 132.58%	72,708 $2.29 Million
Q3 2023 Nov 09, 2023	BUY	$25.44 - $37.35 $362,774 - $532,611	14,260 Added 83.87%	31,262 $798,000
Q2 2023 Aug 11, 2023	SELL	$23.94 - $32.36 $579,443 - $783,241	-24,204 Reduced 58.74%	17,002 $487,000
Q1 2023 May 12, 2023	SELL	$14.72 - $23.97 $646,443 - $1.05 Million	-43,916 Reduced 51.59%	41,206 $987,000
Q4 2022 Feb 08, 2023	BUY	$14.14 - $23.06 $1.15 Million - $1.88 Million	81,642 Added 2346.03%	85,122 $1.44 Million
Q3 2022 Nov 10, 2022	SELL	$13.05 - $22.13 $435,426 - $738,389	-33,366 Reduced 90.56%	3,480 $52,000
Q2 2022 Aug 10, 2022	SELL	$12.26 - $31.17 $2.03 Million - $5.16 Million	-165,389 Reduced 81.78%	36,846 $580,000
Q1 2022 May 16, 2022	BUY	$17.64 - $39.57 $1.82 Million - $4.08 Million	103,205 Added 104.22%	202,235 $5.45 Million
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $317,547 - $441,594	9,285 Added 10.35%	99,030 $3.67 Million
Q3 2021 Nov 15, 2021	BUY	$27.88 - $58.25 $1.55 Million - $3.25 Million	55,774 Added 164.18%	89,745 $4.29 Million
Q2 2021 Aug 13, 2021	SELL	$25.79 - $42.11 $227,957 - $372,210	-8,839 Reduced 20.65%	33,971 $1.15 Million
Q1 2021 May 12, 2021	BUY	$38.75 - $86.92 $568,927 - $1.28 Million	14,682 Added 52.2%	42,810 $1.77 Million
Q4 2020 Feb 11, 2021	BUY	$34.61 - $123.66 $491,462 - $1.76 Million	14,200 Added 101.95%	28,128 $1.22 Million
Q3 2020 Nov 12, 2020	SELL	$37.49 - $63.19 $73,480 - $123,852	-1,960 Reduced 12.34%	13,928 $597,000
Q2 2020 Jul 31, 2020	BUY	$12.66 - $58.27 $197,989 - $911,284	15,639 Added 6280.72%	15,888 $743,000
Q1 2020 May 01, 2020	SELL	$9.31 - $18.26 $2,867 - $5,624	-308 Reduced 55.3%	249 $3,000
Q4 2019 Feb 14, 2020	BUY	$8.93 - $12.41 $4,974 - $6,912	557 New	557 $6,000
Q3 2019 Nov 14, 2019	SELL	$8.8 - $14.5 $25,687 - $42,325	-2,919 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$5.78 - $9.79 $16,871 - $28,577	2,919 New	2,919 $28,000

Others Institutions Holding ARCT

# of Institutions

179

Shares Held

25.6M

Call Options Held

195K

Put Options Held

133K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $439M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account